Essential tremor

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Muzamil Akhtar [2]

Overview

This microchapter is the master overview of essential tremor (ET), the most common adult movement disorder. ET is a clinical syndrome of isolated bilateral upper-limb action (postural and kinetic) tremor present for at least 3 years, with or without tremor of the head, voice, or lower limbs, and without other neurologic signs such as dystonia, ataxia, or parkinsonism. It is diagnosed clinically; no confirmatory laboratory or imaging test exists. First-line therapy is propranolol or primidone, with deep brain stimulation (DBS) or MRI-guided focused ultrasound (MRgFUS) thalamotomy reserved for medically refractory, disabling tremor.

Definition and classification

The 2018 International Parkinson and Movement Disorder Society (IPMDS) consensus replaced older "benign essential tremor" terminology with a two-axis system (Axis 1, clinical syndrome; Axis 2, etiology).[1][2] Operational definitions include:

  • Essential tremor: Isolated action tremor of bilateral upper limbs, ≥3 years' duration, with or without tremor elsewhere, and no other neurologic signs.[3]
  • Essential tremor plus (ET-plus): ET with additional soft signs of uncertain significance—impaired tandem gait, questionable dystonic posturing, mild memory impairment, or a rest tremor component—that do not meet criteria for a separate diagnosis.[4][3]
  • Indeterminate tremor: ET-like features present <3 years.[4]

Epidemiology

ET affects approximately 1% of the population worldwide (pooled prevalence 0.9%), rising sharply with age to about 4.6% to 6.3% in those ≥65 years and >20% in those ≥95 years.[3][5] Age at onset is bimodal, with peaks around the second and sixth decades.[6][7] Most population-based studies show no consistent sex difference, though several report a slight male predominance.[3][5] An estimated 7–10 million people are affected in the US.[8]

Natural history and prognosis

ET typically progresses slowly, with gradual increase in tremor amplitude over years. Later age at onset (≥65 years) is associated with a higher burden of physical and cognitive coexisting conditions.[3]

Pathophysiology

ET is best understood as a network disorder of the cerebello-thalamo-cortical (CTC) pathway rather than a single lesion, and its etiology is heterogeneous.[9][10] Non-mutually-exclusive mechanisms include:[10]

  • Cerebellar GABAergic dysfunction: Post-mortem studies showing reduced GABA receptor density in the dentate nucleus remain debated.[11][12]
  • Synaptic pathology: Climbing fiber–Purkinje cell synaptic pathology with Purkinje cell loss and axonal "torpedoes".[3][9]
  • Olivocerebellar/extra-cerebellar oscillation: Potentially related to β-carboline excitation driving aberrant oscillations.[10]

Cellular bursts in the ventral intermediate (Vim) nucleus of the thalamus correlate strongly with tremor, making Vim the principal surgical target.[3] Propranolol and ethanol both suppress tremor by dampening cerebellar output.[9][3]

Etiology and risk factors

ET is frequently familial with an autosomal dominant pattern; a positive family history is reported in 20–90% of cases, and first-degree relatives have substantially increased risk.[6][3] GWAS have identified associated variants (e.g., LINGO1), but no single causative gene explains most cases.[3]

Proposed environmental contributors include β-carboline alkaloids (harmane) from overcooked meat.[3][10] Tremor amplitude is transiently worsened by caffeine, stress, anxiety, fatigue, and certain drugs, and is characteristically reduced by alcohol.[4]

Clinical features, history, and physical examination

ET produces a 4–12 Hz postural and kinetic tremor of the hands/forearms, often affecting writing, eating, drinking, and fine tasks. Head ("yes-yes"/"no-no") and voice tremor are common.[3][13] Non-motor associations may include mild cognitive (executive/memory) changes, depression/anxiety, hearing impairment, and sleep disturbance.[14][3]

Key history: Age at onset, family history, temporal course, alcohol responsiveness, and exposure to tremorogenic drugs (valproate, SSRIs/SNRIs, lithium, sympathomimetics, neuroleptics, stimulants) or toxins.[4][3]

Physical examination: Characterize activation condition (rest vs postural vs kinetic), distribution, and frequency. Screen for red flags of alternative diagnoses (bradykinesia, rigidity, dystonic posturing, ataxia, focal deficits).[4][3] The TETRAS scale can be used to quantify severity.[3]

Differential diagnosis

The two most common clinical dilemmas are ET vs Parkinson disease (PD) and ET vs dystonic tremor.[15] There is no confirmatory test for ET; basic labs (TSH, electrolytes, liver/kidney function) are used to exclude enhanced physiologic tremor.[3][4] Serum ceruloplasmin should be checked in any action tremor under age 40 to exclude Wilson disease.[15] Brain imaging is not indicated for isolated ET but DaTscan can differentiate ET (normal) from parkinsonian tremor when uncertain.[16]

Table 1. Differentiating Essential Tremor from Mimics
Condition Activation Laterality/frequency Distinguishing features
Essential tremor Postural + kinetic (action) Bilateral, 4–12 Hz Isolated tremor ≥3 yr; tremulous but normal-sized handwriting; alcohol-responsive
Parkinson disease Rest (re-emergent postural) Unilateral onset, 4–6 Hz Bradykinesia, rigidity, micrographia (small, atremulous), hypomimia; tremor increases with mental tasks
Dystonic tremor Position- or task-specific Often unilateral, irregular, <7 Hz Sensory trick, null point, overflow/mirror dystonia, muscle hypertrophy, pain
Enhanced physiologic tremor Postural + kinetic Bilateral, 4–12 Hz Reversible metabolic/drug trigger (thyrotoxicosis, hypoglycemia, caffeine); lower amplitude
Cortical tremor Postural + kinetic 9–18 Hz Coexisting epilepsy/myoclonus, giant SSEPs, refractory to ET therapy
Holmes tremor Rest + postural + kinetic Low (2.5–5 Hz), proximal Follows midbrain/cerebellar outflow lesion

Treatment

Treatment is indicated only when tremor causes functional or psychosocial impairment.[4] Nonpharmacologic measures (occupational therapy, weighted/adaptive utensils, caffeine reduction) help mild symptoms.[4]

First-line pharmacotherapy (AAN Level A, established as effective):[17]

  • Propranolol: 120–240 mg/day; reduces tremor amplitude ~55%; the only FDA-approved drug for ET. Cautions/contraindications: asthma/COPD (bronchospasm), symptomatic bradycardia, hypotension; observe for masked hypoglycemia in insulin-treated diabetes. Propranolol is generally preferred if pharmacotherapy is required during pregnancy.[3][4]
  • Primidone: 250–750 mg/day; ~60% amplitude reduction; frequent early dizziness/nausea/sedation (start low, titrate slowly); contraindicated in porphyria. Carries teratogenicity concerns (phenobarbital metabolite). Combination propranolol + primidone can outperform monotherapy.[3][4]

Second-line agents (AAN Level B, probably effective): topiramate (avoid >200 mg/day due to cognitive effects and paresthesias; carries teratogenicity concerns), gabapentin (monotherapy), atenolol, sotalol, alprazolam.[17][4]

Additional options (AAN Level C, possibly effective): botulinum toxin type A—may help voice, head, and jaw tremor; forearm injection reduces limb tremor amplitude but frequently causes hand weakness without functional gain and has no benefit for horizontal head tremor. Nadolol, nimodipine, and clonazepam are also Level C.[17][4]

  • Note: 30–50% of patients do not respond to propranolol or primidone.[17]

Surgical / procedural therapy (targets the Vim nucleus for medically refractory, disabling tremor):[3]

  • Deep brain stimulation (DBS): Unilateral or bilateral. Adjustable, reversible; a standard preferred for younger patients and those needing bilateral therapy (AAN Level C, possibly effective). Pooled analyses suggest bilateral DBS provides superior tremor suppression to unilateral MRgFUS, whereas unilateral DBS and unilateral MRgFUS are equivalent.[18] Emerging surgical targets include the caudal zona incerta / posterior subthalamic area and dentatorubrothalamic tract (DRTT/CTT). Modern devices feature directional leads, rechargeability (15–20 year lifespan), and remote programming.[19]
  • MRgFUS thalamotomy: Incisionless ablative procedure targeting the Vim (AAN Level C, possibly effective). FDA-approved unilaterally in 2016 on the basis of a sham-controlled RCT (n=76) showing sustained hand-tremor and quality-of-life improvement, with paresthesia/numbness in 14% and gait disturbance in 9% at 12 months. Staged, bilateral MRgFUS was subsequently FDA-approved following a 7-center open-label trial (n=51) showing 66% improvement in CRST parts A+B at 3 months; adverse events (numbness, dysarthria, ataxia) were almost always mild and often transient, with mild ataxia persisting in 6 of 51 patients at 12 months. Ideal for older patients or those with surgical contraindications; persistent complications are more common than with DBS.[20] The American Society for Stereotactic and Functional Neurosurgery (2026) concluded that MRgFUS thalamotomy is a safe, effective, and durable intervention for refractory ET in appropriately selected patients, and that early experience with staged bilateral lesioning appears safe and effective.[21]

Important updates vs older teaching

  • Pathophysiology has shifted from a purely inferior-olive "pacemaker" model toward a cerebellar/dentate GABAergic and Purkinje-cell network model.[4][10][11]
  • ET is increasingly recognized as carrying non-motor burden (mild cognitive change, depression/anxiety, hearing loss, sleep disruption), reframing the older "purely motor, benign" teaching.[3][14]
  • TAPS wrist neuromodulation is an FDA-cleared noninvasive wrist-worn adjunct (Cala device) delivering median/radial nerve stimulation calibrated to tremor frequency; randomized and open-label data show improvement in TETRAS and activities-of-daily-living scores with transient (~1 hour) tremor reduction per session.[22][23]

Areas of uncertainty and controversy

  • Nosology: The 2018 IPMDS ET-plus category is pragmatic but contested; critics argue it lacks biological validity and creates arbitrary boundaries with PD and dystonia.[4][15]
  • GABA hypothesis: Dentate GABA-receptor deficits are reported in some studies but not reproduced consistently.[11][12]
  • Neurodegeneration: Whether Purkinje-cell loss is a true degenerative feature or a nonspecific/aging finding is unresolved.[4][10]
  • DBS vs MRgFUS: No adequately powered head-to-head RCT exists; choice rests on reversibility, adjustability, patient age, and need for bilateral therapy.[18][19]

High-yield clinical pearls

  • Action tremor + normal-sized (tremulous) handwriting + alcohol responsiveness + positive family history is the classic ET quartet.[16][4]
  • Micrographia and rest tremor point to Parkinson disease, not ET.[16]
  • Always check ceruloplasmin/Wilson workup in an action tremor presenting before age 40.[15]
  • Combining propranolol + primidone can help when either monotherapy is only partially effective.[3][4]
  • DaTscan is normal in ET and abnormal in parkinsonian tremor—useful when the exam is equivocal.[16]

Common pitfalls

  • Labeling any bilateral hand tremor as ET without excluding enhanced physiologic tremor (thyrotoxicosis, hypoglycemia, drugs, caffeine).[4]
  • Missing early Parkinson disease: a re-emergent postural tremor and subtle bradykinesia can masquerade as ET.[16]
  • Under-dosing first-line agents: propranolol is frequently stopped prematurely before reaching 120–240 mg/day, and primidone is abandoned because of transient first-dose reactions rather than slow titration.[14][3]
  • Prescribing propranolol without screening for contraindications like asthma/COPD or symptomatic bradycardia.[3]
  • Calling residual tremor "treatment failure" when 30–50% of patients simply do not respond to first-line drugs and warrant referral for interventional therapy.[14]

References

  1. ↑ Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, Raethjen J, Stamelou M, Testa CM, Deuschl G (January 2018). "Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society". Mov Disord. 33 (1): 75–87. doi:10.1002/mds.27121. PMC 6530552 Check |pmc= value (help). PMID 29193359.
  2. ↑ Latorre A, Hallett M, Deuschl G, Bhatia KP (April 2022). "The MDS consensus tremor classification: The best way to classify patients with tremor at present". J Neurol Sci. 435: 120191. doi:10.1016/j.jns.2022.120191. PMID 35247714 Check |pmid= value (help).
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 3.22 3.23 Haubenberger D, Hallett M. (2018). "Essential Tremor". The New England Journal of Medicine. 378 (19): 1802–1810. doi:10.1056/NEJMcp1707928.
  4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 Elias WJ, Shah BB. (2024). "Essential Tremor". JAMA. 332 (5): 418–419. doi:10.1001/jama.2024.7475.
  5. ↑ 5.0 5.1 Louis ED, Ferreira JJ. (2010). "How Common Is the Most Common Adult Movement Disorder? Update on the Worldwide Prevalence of Essential Tremor". Movement Disorders : Official Journal of the Movement Disorder Society. 25 (5): 534–41. doi:10.1002/mds.22838.
  6. ↑ 6.0 6.1 Kuhlenbäumer G, Hopfner F, Deuschl G. (2014). "Genetics of Essential Tremor: Meta-Analysis and Review". Neurology. 82 (11): 1000–7. doi:10.1212/WNL.0000000000000211.
  7. ↑ Louis ED, Ford B, Barnes LF. (2000). "Clinical Subtypes of Essential Tremor". Archives of Neurology. 57 (8): 1194–8. doi:10.1001/archneur.57.8.1194.
  8. ↑ Zesiewicz TA, Sullivan KL, Ponce de Leon M, Bennett A, Hohler AD. (2017). "Quality Improvement in Neurology: Essential Tremor Quality Measurement Set". Neurology. 89 (12): 1291–1295. doi:10.1212/WNL.0000000000004372.
  9. ↑ 9.0 9.1 9.2 Benarroch E. (2024). "What Is the Role of the Dentate Nucleus in Normal and Abnormal Cerebellar Function?". Neurology. 103 (3): e209636. doi:10.1212/WNL.0000000000209636.
  10. ↑ 10.0 10.1 10.2 10.3 10.4 10.5 Pan MK, Kuo SH. (2022). "Essential Tremor: Clinical Perspectives and Pathophysiology". Journal of the Neurological Sciences. 435: 120198. doi:10.1016/j.jns.2022.120198.
  11. ↑ 11.0 11.1 11.2 Paris-Robidas S, Brochu E, Sintes M; et al. (2012). "Defective Dentate Nucleus GABA Receptors in Essential Tremor". Brain : A Journal of Neurology. 135 (Pt 1): 105–16. doi:10.1093/brain/awr301.
  12. ↑ 12.0 12.1 Bellows S, Jimenez-Shahed J. (2022). "Is Essential Tremor a Disorder of GABA Dysfunction? No". International Review of Neurobiology. 163: 285–310. doi:10.1016/bs.irn.2022.02.006.
  13. ↑ Wagle Shukla A, Panyakaew P. (2026). "Neurophysiological Basis of Tremor Disorders: Parkinson's Disease, Essential Tremor, Tremor in Dystonia, and Holmes Tremor". Seminars in Neurology. doi:10.1055/a-2870-6059.
  14. ↑ 14.0 14.1 14.2 14.3 Shanker V. (2019). "Essential Tremor: Diagnosis and Management". BMJ (Clinical Research Ed.). 366: l4485. doi:10.1136/bmj.l4485.
  15. ↑ 15.0 15.1 15.2 15.3 Louis ED. (2005). "Essential Tremor". The Lancet. Neurology. 4 (2): 100–10. doi:10.1016/S1474-4422(05)00991-9.
  16. ↑ 16.0 16.1 16.2 16.3 16.4 Reich SG. (2020). "Does This Patient Have Parkinson Disease or Essential Tremor?". Clinics in Geriatric Medicine. 36 (1): 25–34. doi:10.1016/j.cger.2019.09.015.
  17. ↑ 17.0 17.1 17.2 17.3 Zesiewicz TA, Elble RJ, Louis ED; et al. (2011). "Evidence-Based Guideline Update: Treatment of Essential Tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 77 (19): 1752–5. doi:10.1212/WNL.0b013e318236f0fd.
  18. ↑ 18.0 18.1 Giordano M, Caccavella VM, Zaed I; et al. (2020). "Comparison Between Deep Brain Stimulation and Magnetic Resonance-Guided Focused Ultrasound in the Treatment of Essential Tremor: A Systematic Review and Pooled Analysis of Functional Outcomes". Journal of Neurology, Neurosurgery, and Psychiatry. 91 (12): 1270–1278. doi:10.1136/jnnp-2020-323216.
  19. ↑ 19.0 19.1 Venkatesan S, Sorrentino Z, Mampre D, Chandra V, Hilliard J. (2026). "Contemporary and Evolving Perspectives on Surgical Therapies for Essential Tremor: Deep Brain Stimulation and Focused Ultrasound". Expert Review of Neurotherapeutics. 26 (5): 443–460. doi:10.1080/14737175.2026.2642844.
  20. ↑ Kaplitt MG, Krishna V, Eisenberg HM, Elias WJ, Ghanouni P, Baltuch GH, Rezai A, Halpern CH, Dalm B, Fishman PS, Buch VP, Moosa S, Sarva H, Murray AM (September 2024). "Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor: An Open-Label Clinical Trial". JAMA Neurol. 81 (9): 939–946. doi:10.1001/jamaneurol.2024.2295. PMC 11287440 Check |pmc= value (help). PMID 39073822 Check |pmid= value (help).
  21. ↑ Hamani C, Elias WJ, Baltuch GH, Gross RE, Rosenow JM, Schwalb JM, Air EL, Machado AG, Sweet J, Willie JT, Rolston JD, Englot DJ, Lipsman N, Zemmar A, Neimat JS, Cosgrove GR, Asaad WF, Ali R, Pilitsis JG, Danish SF (July 2026). "Magnetic resonance-guided focused ultrasound for the management of tremor: update on the position statement of the American Society for Stereotactic and Functional Neurosurgery". J Neurosurg. 145 (1): 4–12. doi:10.3171/2025.11.JNS251828. PMID 41894813 Check |pmid= value (help).
  22. ↑ Ondo WG, Lv W, Zhu X, Hu Y, Isaacson SH, Yuan Y, Espay AJ, Kreitzman D, Kuo SH, Brillman S, Shill HA, Lyons KE, Yang Z, Zhao Q, Zhang Z, Pahwa R (December 2025). "Transcutaneous Peripheral Nerve Stimulation for Essential Tremor: A Randomized Clinical Trial". JAMA Neurol. 82 (12): 1235–1242. doi:10.1001/jamaneurol.2025.3905. PMID 41114984 Check |pmid= value (help).
  23. ↑ Pahwa R, Dhall R, Ostrem J, Gwinn R, Lyons K, Ro S, Dietiker C, Luthra N, Chidester P, Hamner S, Ross E, Delp S (July 2019). "An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor". Neuromodulation. 22 (5): 537–545. doi:10.1111/ner.12930. PMC 6766922 Check |pmc= value (help). PMID 30701655.
Retrieved from "https://www.wikidoc.org/index.php?title=Essential_tremor&oldid=1745640"